Our analysis revealed a significant decrease in CLDN1 mRNA expression in CytoMix-treated KCs compared to controls at 48 and 72 h post-inflammation induction, as illustrated in Figure 1D. This finding suggests that the treatment with CytoMix induces changes in CLDN1 gene expression that can potentially modify the keratinocyte barrier status, resulting in lower CI/nCI values in psoriasis-like KCs compared to their controls. The gene discussed is CLDN1; the disease is dry eye syndrome.